Bolt Biotherapeutics (BOLT) EBITDA (2020 - 2025)
Historic EBITDA for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to -$7.1 million.
- Bolt Biotherapeutics' EBITDA rose 5211.36% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.9 million, marking a year-over-year increase of 3370.63%. This contributed to the annual value of -$63.1 million for FY2024, which is 759.51% up from last year.
- Latest data reveals that Bolt Biotherapeutics reported EBITDA of -$7.1 million as of Q3 2025, which was up 5211.36% from -$8.6 million recorded in Q2 2025.
- In the past 5 years, Bolt Biotherapeutics' EBITDA ranged from a high of -$7.1 million in Q3 2025 and a low of -$27.4 million during Q4 2021
- Its 5-year average for EBITDA is -$17.8 million, with a median of -$17.9 million in 2023.
- As far as peak fluctuations go, Bolt Biotherapeutics' EBITDA plummeted by 13410.0% in 2021, and later soared by 5940.67% in 2025.
- Quarter analysis of 5 years shows Bolt Biotherapeutics' EBITDA stood at -$27.4 million in 2021, then soared by 30.0% to -$19.2 million in 2022, then rose by 7.89% to -$17.7 million in 2023, then rose by 9.31% to -$16.0 million in 2024, then surged by 55.45% to -$7.1 million in 2025.
- Its last three reported values are -$7.1 million in Q3 2025, -$8.6 million for Q2 2025, and -$11.1 million during Q1 2025.